In order to create alternative meat utilizing 3D bioprinting technology, CJ Foods, a division of South Korean company CJ CheilJedang, said that it has signed a joint development agreement (JDA) with T&R Biofab. T&R Biofab is a medical technology firm that creates artificial tissues utilizing its top-notch regenerative medicine 3D bioprinting technology.
The two Korean businesses will work together to raise new plant-based alternative protein products to customer expectations for flavor, texture, appearance, and nutrition by utilizing synergies between the food industry and the 3D printing medical sector. Beyond what is already available, plant-based alternative protein food items are viewed as fresh development engines for both businesses.
Bloomberg Intelligence predicts that the market for plant-based foods would increase quickly from USD 24.9 billion in 2020 to USD 162 billion by 2030. Beyond concerns for animal welfare, plant-based food has become a significant trend that is valued for its advantages in terms of health, nutrition, and the environment. However, there is still a problem with producing food that has the genuine mouthfeel and texture of animal products.
“At CJ Foods, we recognize that breakthrough innovation happens at the interface of distinctly different proficiencies and industries,” according to Florian Viton, senior vice president, Strategic Innovation at CJ Foods. “We see our partnership with T&R Biofab as a unique opportunity to create alternative protein offerings that truly surpass the limitations hindering today’s plant-based products. This exciting collaboration is part of CJ Food’s broader strategy to accelerate our pace of innovation and seed new growth engines in support of CJ Food’s global ambitions.”
Find out more at: https://www.cj.co.kr/en